drugset
drugset / Trial / NCT07156773

The Study is Being Conducted to Evaluate the Safety and Efficacy of XJN010 Nasal Spray in Patients With Parkinson's Disease Experiencing Off Episodes

NCT07156773 ↗

Phase 2 Recruiting 84 enrolled Guangzhou Novaken Pharm Co., Ltd.
RandomizedParallel-groupSingle-blindTreatment

Summary

The study is being conducted to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of XJN010 Nasal Spray in Patients with Parkinson's Disease Experiencing Off Episodes

Timeline

Start
2025-09-03
Primary completion
2026-03-30
Completion
2026-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject XJN010 Unknown — Intranasal

Indications

Parkinson disease